Arbutus Biopharma Corporation (GB:0SGC)

Arbutus Biopharma (0SGC) Income Statement


Arbutus Biopharma Income Statement

Last quarter (Q1 2023), Arbutus Biopharma's total revenue was $5.51M, a decrease of -56.21% from the same quarter last year. In Q1, Arbutus Biopharma's net income was $32.17M. See Arbutus Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 31.95M$ 39.02M$ 10.99M$ 6.91M$ 6.01M$ 5.95M
Cost of Revenue
---$ 47.48M$ 57.60M$ 57.93M
Gross Profit
$ 12.93M$ 39.02M-$ -40.57M$ -51.59M$ -51.99M
Operating Expense
$ 54.16M$ -104.47M$ 82.64M$ 64.18M$ 77.36M$ 76.12M
Operating Income
$ -21.59M$ -63.22M$ -71.65M$ -57.27M$ -71.34M$ -70.17M
Net Non Operating Interest Income Expense
$ 1.88M$ 466.00K$ -2.73M$ -3.27M$ 3.00K$ 2.82M
Other Income Expense
$ 422.00K$ 4.39M$ -1.87M$ -3.21M$ -95.04M$ 6.01M
Pretax Income
$ -69.51M$ -67.17M$ -76.25M$ -63.74M$ -166.38M$ -61.34M
Tax Provision
-$ 4.44M-$ 0.00$ -12.66M$ -4.28M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -21.01M$ -71.61M$ -88.39M$ -75.87M$ -164.87M$ -67.15M
Basic EPS
$ -0.45$ -0.46$ -0.83$ -1.00$ -2.89$ -1.21
Diluted EPS
$ -0.45$ -0.46$ -0.83$ -1.00$ -2.89$ -1.21
Basic Average Shares
$ 612.33M$ 150.94M$ 106.24M$ 75.84M$ 57.09M$ 55.30M
Diluted Average Shares
$ 612.33M$ 150.94M$ 106.24M$ 75.84M$ 57.09M$ 55.30M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 54.16M$ -104.47M$ 82.64M$ 64.18M$ 77.36M$ 76.12M
Net Income From Continuing And Discontinued Operation
$ -69.51M$ -71.61M$ -76.25M$ -63.74M$ -153.72M$ -57.06M
Normalized Income
$ -31.32M-$ -74.38M$ -63.08M$ -86.72M$ -37.89M
Interest Expense
$ 911.00K-$ 2.86M$ 4.01M$ 2.11M$ 226.00K
$ -70.31M$ -67.63M$ -73.39M$ -59.73M$ -164.27M$ -61.12M
$ -69.58M$ -66.28M$ -71.64M$ -57.76M$ -162.24M$ -58.94M
Currency in USD

Arbutus Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis